Unichem Labs. (UNICHEMLAB)

FairStock Score: 35/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with what I see: a pharmaceutical business with a FairStock Score of 1 and a Piotroski F-Score of 3. That already tells me the recent fundamentals are weak. Unichem's sales fell 2.24% and profits crashed 69.96%. No amount of industry tailwind can excuse that kind of earnings collapse in a stable pharma market. The stock is at ₹385.40, against book value of ₹338.54, so I am paying a 14% premium to tangible net assets. Historically, I have no problem holding a good business at fair price, but I do not yet see evidence of a good business here. ROE is only 9.56% and ROCE 6.24%; both are below what I expect from a company with pricing power. The balance sheet is respectable—debt/equity 0.21—and promoters own 70.22%, which aligns owners and management. Yet no dividend is paid, so the shareholder is entirely dependent on capital gains. The latest quarter shows net profit of ₹264 Cr on sales of ₹521 Cr; that is an unusually high margin and I would immediately ask whether it comes from recurring operations or a one-time gain. Since annual profit growth is -69.96%, the quarterly number clearly is not the norm. A P/E of 23.17 on falling earnings is not a margin of safety. The shares have fallen from ₹687.20 to around ₹385.40, but a lower price does not automatically make it cheap. I need to see stable profit margins, a rebound in sales growth, and better returns on capital before I can call this a Graham-style investment. Right now it has more of the smell of a speculative turnaround than a concrete value proposition.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer